Medicus Pharma completes enrollment for Phase 2 basal cell carcinoma study

Medicus Pharma (MDCX) completed enrollment of 90 patients across nine U.S. sites in its Phase 2 SKNJCT-003 trial of a doxorubicin microneedle array (D‑MNA) for nodular basal cell carcinoma, randomized 1:1:1 to placebo, 100 µg and 200 µg doses (200 µg was the top dose in Phase 1 SKNJCT-001). The company expects topline results before end‑Q1 2026 and plans to request an end‑of‑Phase‑2 meeting with the FDA in H1 2026 as it advances a non‑invasive, localized immune therapy targeting an estimated ~$2 billion market opportunity. Management cited interim Q1 2025 data showing >60% clinical clearance in 26 patients, but final efficacy and regulatory prospects will hinge on the upcoming readout.

Analysis

Medicus Pharma announced completion of enrollment for its Phase 2 SKNJCT-003 trial with 90 patients randomized 1:1:1 across nine U.S. sites to placebo microneedle array (P-MNA), 100 µg D-MNA and 200 µg D-MNA; the 200 µg dose was the highest dose used in the company’s Phase 1 SKNJCT-001 completed in March 2021. Completing enrollment removes recruitment risk and establishes a clear statistical timeline — roughly 30 patients per arm — for the planned topline readout expected before end‑Q1 2026. The company plans to request an end‑of‑Phase‑2 meeting with the FDA in H1 2026, creating a near‑term regulatory catalyst contingent on the topline outcome, and management points to interim Q1 2025 data showing >60% clinical clearance in 26 patients as a positive signal. Management frames the opportunity as approximately $2 billion; however, the dataset remains small and the pivotal/regulatory pathway will hinge on both efficacy and safety readouts, so the program carries binary event risk where trial results and subsequent FDA guidance will materially affect valuation and development strategy.

Key Decisions for Investors

• Consider a small, tactical position size ahead of the topline readout given enrollment completion and positive interim signals, but cap exposure to reflect the binary Phase 2 risk
• Prioritize monitoring the topline release for per‑arm clinical clearance rates and safety events and track timing and content of the planned end‑of‑Phase‑2 FDA meeting in H1 2026 as primary catalysts
• Avoid enlarging positions until topline efficacy/safety and FDA feedback reduce uncertainty, because the trial is effectively ~30 patients per arm and interim data came from only 26 patients
• Watch for company disclosures on analysis populations, statistical significance thresholds and plans for a pivotal study after the FDA meeting to reassess the investment thesis